Namal Chithranga Warshakoon

This inventor holds 15 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Akebia Therapeutics, Inc., The Procter Gamble Company, Warner Chilcott Company, LLC. Active years: 2005-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Namal Chithranga Warshakoon. Retrieved from https://idiyas.com/inventor/namal-chithranga-warshakoon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 4)

% Patents Active = 80.0

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 3.9

ph-index = 11

Forward Citations = 273(Granted Patents)

Location History:

Mason, OH (US) (2005 - 2013)
Cary, NC (US) (2013 - 2024)

Company Filing History:

11 out of 38

Akebia Therapeutics, Inc.

patents

2 out of 17,173

The Procter Gamble Company

patents

2 out of 39

Warner Chilcott Company, LLC

patents

Years Active: 2005-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11883386 - Prolyl hydroxylase inhibitors and methods of use (2024-01-30),

2. 11426393 - Prolyl hydroxylase inhibitors and methods of use (2022-08-30),

3. 10729681 - Prolyl hydroxylase inhibitors and methods of use (2020-08-04),

4. RE47437 - Prolyl hydroxylase inhibitors and methods of use (2019-06-17),

5. 9598370 - Prolyl hydroxylase inhibitors and methods of use (2017-03-21),

6. 8940773 - Prolyl hydroxylase inhibitors and methods of use (2015-01-27),

7. 8722895 - Prolyl hydroxylase inhibitors and method of use (2014-05-13),

8. 8598210 - Prolyl hydroxylase inhibitors and methods of use (2013-12-03),

9. 8343952 - Prolyl hydroxylase inhibitors and methods of use (2013-01-01),

10. 8323671 - Prolyl hydroxylase inhibitors and methods of use (2012-12-04),

11. 8133894 - N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones (2012-03-13),

12. 7811595 - Prolyl hydroxylase inhibitors and methods of use (2010-10-12),

13. 7790748 - N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones (2010-09-07),

14. 6946479 - N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones (2005-09-20),

15. 6930117 - N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones (2005-08-16),

Title: Innovations and Contributions of Namal Chithranga Warshakoon

Introduction

Namal Chithranga Warshakoon, based in Mason, OH, is an accomplished inventor with a significant portfolio of 15 patents. His innovative contributions primarily focus on medical therapies aimed at addressing critical health conditions, including cardiovascular diseases and anemia.

Latest Patents

Among his notable inventions are the patents related to prolyl hydroxylase inhibitors, which enhance the body's ability to manage various health issues. These patents describe the use of HIF-1α prolyl hydroxylase inhibitors in compositions that serve to treat Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. His work in this area demonstrates a commitment to improving patient outcomes through innovative medical solutions.

Career Highlights

Throughout his career, Namal has made impactful contributions while working with prominent companies such as Akebia Therapeutics, Inc. and Warner Chilcott Company, LLC. His role in these organizations has further allowed him to refine his expertise and develop groundbreaking therapies that can significantly improve patients’ lives.

Collaborations

Namal has collaborated with several talented individuals in the research and development field, including Richard Masaru Kawamoto and Shengde Wu. These partnerships have played a crucial role in driving forward his innovative projects and expanding the scope of his inventions.

Conclusion

Namal Chithranga Warshakoon stands out as a vital contributor in the field of medical innovation. His extensive patent portfolio and collaborations exemplify his dedication to advancing healthcare through inventive solutions. As he continues to work towards addressing critical health issues, his future contributions are highly anticipated in both the medical and scientific communities.

Profile summary based on public USPTO records.